HC Wainwright Forecasts Dare Bioscience FY2030 Earnings

Dare Bioscience, Inc. (NASDAQ:DARE) – Equities research analysts at HC Wainwright issued their FY2030 EPS estimates for shares of Dare Bioscience in a report issued on Friday, May 15th. HC Wainwright analyst D. Tsao forecasts that the biotechnology company will post earnings per share of $6.54 for the year. The consensus estimate for Dare Bioscience’s current full-year earnings is ($0.97) per share.

Dare Bioscience (NASDAQ:DARE) last announced its earnings results on Thursday, May 14th. The biotechnology company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.13. The company had revenue of $0.15 million for the quarter, compared to the consensus estimate of $0.03 million.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Dare Bioscience in a report on Monday, April 20th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $10.00.

Dare Bioscience Stock Performance

Shares of DARE stock opened at $2.25 on Monday. The company has a market capitalization of $33.71 million, a price-to-earnings ratio of -2.37 and a beta of 1.09. The company has a 50-day simple moving average of $2.01 and a 200 day simple moving average of $1.92. Dare Bioscience has a 52 week low of $1.27 and a 52 week high of $9.19.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of DARE. AMH Equity Ltd lifted its stake in shares of Dare Bioscience by 20.0% in the third quarter. AMH Equity Ltd now owns 232,373 shares of the biotechnology company’s stock valued at $488,000 after buying an additional 38,770 shares in the last quarter. Virtu Financial LLC bought a new position in shares of Dare Bioscience during the third quarter valued at about $37,000. Raymond James Financial Inc. lifted its position in shares of Dare Bioscience by 810.6% during the third quarter. Raymond James Financial Inc. now owns 15,334 shares of the biotechnology company’s stock valued at $32,000 after purchasing an additional 13,650 shares in the last quarter. Finally, LPL Financial LLC bought a new position in shares of Dare Bioscience during the fourth quarter valued at about $28,000. 6.70% of the stock is owned by institutional investors.

Dare Bioscience News Roundup

Here are the key news stories impacting Dare Bioscience this week:

• Positive Sentiment: Daré announced it has initiated a Phase 2 study of DARE-HPV, a novel, non-surgical treatment for persistent high-risk HPV infection. The program targets a large unmet market with no FDA-approved therapies and is supported by a $10 million ARPA-H government contract, with topline data expected in 2027. Article Title
• Positive Sentiment: Brookline Capital Markets raised its FY2026 EPS estimate for Daré Bioscience to a smaller loss of $1.37 per share, up from $1.50, suggesting slightly improved expectations for near-term results.
• Neutral Sentiment: HC Wainwright issued fresh earnings estimates across 2026-2029, including losses in the near term but projecting a return to profitability later in the forecast period. The updates were mostly model revisions rather than a new fundamental catalyst.
• Neutral Sentiment: HC Wainwright also lowered/updated quarterly expectations for 2026, with Q2 and Q4 still expected to be unprofitable and Q3 projected to show a modest profit, reflecting a mixed outlook for the company’s development timeline.

About Dare Bioscience

Dare Bioscience, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for women’s reproductive health. The company’s flagship development candidate is Ovaprene, a monthly, self-administered, non-hormonal contraceptive vaginal ring designed to offer an alternative to traditional hormone-based birth control methods. Through its proprietary intravaginal drug delivery platform, Dare seeks to address unmet medical needs in gynecology and contraception with products that prioritize efficacy, safety and ease of use.

In addition to its lead contraceptive program, Dare is advancing a pipeline of early-stage assets aimed at treating gynecologic conditions through local, non-systemic drug delivery.